Show simple item record

dc.contributor.authorvon der Maase, Hen
dc.contributor.authorGeertsen, Pen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorJasmin, Cen
dc.contributor.authorMercatello, Aen
dc.contributor.authorFosså, S Den
dc.contributor.authorSymann, Men
dc.contributor.authorStoter, Gen
dc.contributor.authorNagel, Gen
dc.contributor.authorIsrael, Len
dc.date.accessioned2010-07-14T17:06:57Z
dc.date.available2010-07-14T17:06:57Z
dc.date.issued1991
dc.identifier.citationRecombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study. 1991, 27 (12):1583-9 Eur J Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid1782066
dc.identifier.urihttp://hdl.handle.net/10541/107658
dc.description.abstractThis multinational, multicentre study represents the introduction of recombinant interleukin-2 (rIL-2) in Europe. From December 1987 to June 1989, 57 eligible patients with metastatic renal cell cancer were treated with rIL-2 administered as continuous intravenous infusion. 8 out of 51 evaluable patients responded (16%), 2 complete remission (CR) and 6 partial remission (PR). 10 patients had no change (20%). The response duration for CR was 209 and 394+ days. The median response duration for PR was 371 (range 140-506+) days. Dose-limiting grade 3-4 toxicities were hypotension in 52% of the patients, arrhythmia (4%), dyspnoea (8%), creatinine rise (4%), peripheral neurotoxicity (10%) and central neurotoxicity (10%). Toxicities most often recovered solely on interrupted therapy. 2 patients died due to catheter-related septicaemia and one patient died of rIL-2 induced renal failure. The study confirmed the antitumour efficacy of rIL-2 in renal cell cancer. Toxicities were numerous, but manageable by close observation in a normal oncology ward without routine use of an intensive care unit.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnemia
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshDrug Evaluation
dc.subject.meshFatigue
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypotension
dc.subject.meshInterleukin-2
dc.subject.meshKidney Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRecombinant Proteins
dc.subject.meshTime Factors
dc.titleRecombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Herlev University Hospital, Copenhagen, Denmark.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractThis multinational, multicentre study represents the introduction of recombinant interleukin-2 (rIL-2) in Europe. From December 1987 to June 1989, 57 eligible patients with metastatic renal cell cancer were treated with rIL-2 administered as continuous intravenous infusion. 8 out of 51 evaluable patients responded (16%), 2 complete remission (CR) and 6 partial remission (PR). 10 patients had no change (20%). The response duration for CR was 209 and 394+ days. The median response duration for PR was 371 (range 140-506+) days. Dose-limiting grade 3-4 toxicities were hypotension in 52% of the patients, arrhythmia (4%), dyspnoea (8%), creatinine rise (4%), peripheral neurotoxicity (10%) and central neurotoxicity (10%). Toxicities most often recovered solely on interrupted therapy. 2 patients died due to catheter-related septicaemia and one patient died of rIL-2 induced renal failure. The study confirmed the antitumour efficacy of rIL-2 in renal cell cancer. Toxicities were numerous, but manageable by close observation in a normal oncology ward without routine use of an intensive care unit.


This item appears in the following Collection(s)

Show simple item record